 At SRI, he also managed contract research for pharmaceutical and biotech companies and worked in drug development and consulting teams for domestic and international pharma and biotech companies.He led or was part of drug and associated companion diagnostic product development teams transitioning pre-clinical small molecule drugs into the clinic and he performed his doctoral work on small molecule anti-cancer drugs.Before starting Colby Pharmaceutical Company, Zarling was a president and CEO of Pangene Corporation (PGC, Mt View, CA), a service company which provided drug and drug target development services in pharmaceuticals, genomics & cancer.